SubHero Banner

Krazati (adagrasib) – New orphan drug approval

December 12, 2022 - Mirati Therapeutics announced the FDA approval of Krazati (adagrasib), for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

Download PDF